MICODERIL SOLUTION FOR EXTERNAL USE OF 1% 20 ML

Latin name

Mycoderil

Release form

Solution for external use.

Packaging

Bottle dropper 20 ml.

Pharmacology

Antifungal drug for external use, belonging to the class of allylamino. The main component is naftifine. The mechanism of action is associated with inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is part of the cell wall of the fungus. Naftifine, affecting squalene epoxidase, does not affect the cytochrome P-450 system.

It has a wide range of antifungal action, is active against dermatomycetes, yeast and mold fungi - the main causative agents of fungal diseases of the skin and nails. It has a high antifungal activity and has a primary fungicidal effect - causes the death of fungal cells. It has antibacterial activity against gram-positive and gram-negative microorganisms that can cause secondary bacterial infections. It has an anti-inflammatory effect, which contributes to the rapid disappearance of symptoms of inflammation (redness, swelling, itching).

Indications

• fungal infections of smooth skin and skin folds, including athlete's hand and foot, especially caused by Epidermophyton floccosum, trichophytia, incl. caused by Trichophyton rubrum and Trichophyton mentagrophytes;
• interdigital mycoses (tinea manum, tinea pedum);
• nail fungal infections (onychomycosis);
• skin candidiasis;
• pityriasis versicolor;
• inflammatory dermatomycosis (with or without itching);
• mycoses with secondary bacterial infection;
• mycosis of the external auditory canal.

MYCODERIL solution is effective in treating mycoses affecting areas of the skin with hyperkeratosis, as well as in areas of hair growth.

Contraindications

Hypersensitivity to the components of the drug, drawing on an open wound surface.

Pregnanacy and breastfeeding

Teratogenic effects. In reproduction studies in rats and rabbits when naftifine was administered orally in doses 150 times or more higher than the dose for humans when applied topically, there were no significant fertility disorders or harm to the fetus caused by naftifin.

In pregnancy - with caution (adequate and strictly controlled studies in pregnant women were not performed).

Category of action on the fetus by the FDA - B.

It is not known whether naftifine passes into breast milk. Since many drugs are excreted in the milk of women, caution should be exercised when using during breastfeeding.

Special notes

Use only externally. Contact with the mucous membranes of the eyes, nose, oral cavity, etc. should be avoided. Do not use tight dressings or wrapping the affected surfaces without consulting a doctor. If you experience signs of hypersensitivity, treatment is canceled.

Active ingredient

In 1 ml.agents: naftifine hydrochloride - 10 mg.,

Excipients: propylene glycol - 50 mg, ethanol (ethyl alcohol 95%) - 400 mg, purified water - up to 1 ml.

Dosage and administration

In dermatomycosis and candidiasis of the skin.

The solution is applied 1 time per day on the affected skin surface and adjacent areas after thorough cleaning and drying, capturing about 1 cm of healthy skin at the edges of the affected area. Duration of treatment: for ringworms - 2-4 weeks (up to 8 weeks if necessary), for candidiasis - 4 weeks.

With lesions of the nails (onychomycosis).

Before the first use of peparate, the affected part of the nail is removed as much as possible with scissors and a nail file. The drug is used 2 times a day, the duration of treatment is up to 6 months. To prevent a recurrence of infection, you should continue to use the drug for at least two weeks after the disappearance of the clinical symptoms.

Adverse effects

Local reactions: dry skin, redness, burning, itching, irritation.

Drug interactions

No interaction with other drugs has been noted.

Overdosage

No cases of overdose have been reported.

Storage conditions

At temperatures not above 25 ° C in the reach of children.